Table 3.
Gastric cancer characteristics (N = 157)
| Characteristics | |
|---|---|
| ECOG status, n(%) | |
| 0 | 0 (0%) |
| 1 | 102 (65.0%) |
| 2 | 35 (22.3%) |
| 3 | 15 (9.6%) |
| 4 | 4 (2.5%) |
| Missing | 1 (0.6%) |
| Endoscopy results, n(%) | |
| Penetrating | 111 (70.7%) |
| Protruding | 15 (9.6%) |
| Miscellaneous | 6 (3.8%) |
| Superficial | 3 (1.9%) |
| Linitis | 3 (1.9%) |
| Not applicable | 15 (9.6%) |
| Not done | 4 (2.5%) |
| CT scan results, n(%) | |
| Coeliac lymphadenopathy | 28 (17.8%) |
| Liver metastasis | 19 (12.1%) |
| Other metastasis (bone, lung, ovarian, etc.) | 69 (43.9%) |
| No metastasis | 30 (19.1%) |
| Missing | 11 (7.0%) |
| Chest x-ray results, n(%) | |
| Normal | 18 (11.5%) |
| Central infiltration | 2 (1.3%) |
| Other | 8 (5.1%) |
| Missing | 129 (82.2%) |
| Laboratory results, mean ± standard deviation | |
| CA 19–9 (U/mL) | 1,122.00 ± 2,493.00 |
| CEA (ng/ml) | 91.43 ± 419.01 |
| Hemoglobin (g/dL) | 11.50 ± 2.20 |
| Red blood cells count (10^12/L) | 4.19 ± 0.76 |
| White blood cells count (10^9/L) | 7.30 ± 3.40 |
| Platelets count (10^9/L) | 334.00 ± 254.00 |
| Lymphocytes count (%) | 23.30 ± 12.90 |
| Neutrophils count (%) | 58.00 ± 21.50 |
| Abnormal results, n(%) | |
| Hemoglobin | 73 (46.5%) |
| Red blood cells | 48 (30.6%) |
| Lymphocytes | 29 (18.5%) |
| Neutrophils | 26 (16.6%) |
| White blood cells | 25 (15.9%) |
| Monocytes | 19 (12.1%) |
| CA | 14 (8.9%) |
| Eosinophils | 14 (8.9%) |
| CEA | 9 (5.7%) |
| Vitamin B12 | 6 (3.8%) |
| Basophils | 5 (3.2%) |
| Gastric cancer stage, n(%) | |
| IA | 3 (1.9%) |
| IB | 2 (1.3%) |
| II | 33 (21.0%) |
| IIIA | 12 (7.6%) |
| IIIB | 19 (12.1%) |
| IV | 76 (48.4%) |
| Not applicable | 12 (7.6%) |
| Sites of metastases, n(%) | |
| Bone | 5 (3.2%) |
| Brain | 1 (0.6%) |
| Liver | 25 (15.9%) |
| Lung | 5 (3.2%) |
| NA | 2 (1.3%) |
| No metastasis | 79 (50.3%) |
| Other | 40 (25.5%) |
| Histology results, n(%) | |
| Hepatoid adenocarcinoma | 1 (0.6%) |
| Mucinous adenocarcinoma | 7 (4.5%) |
| Other | 19 (11.5%) |
| Papillary adenocarcinoma | 3 (1.9%) |
| Signet-ring cell carcinoma | 34 (21.7%) |
| Tubular adenocarcinoma, moderately differentiated | 44 (28.0%) |
| Tubular adenocarcinoma, well differentiated | 11 (7.0%) |
| Tubular adenocarcinoma, poorly differentiated | 38 (24.2%) |
| Undifferentiated carcinoma | 1 (0.6%) |
Abbreviations: CA Cancer antigen, CEA Carcinoembryonic antigen, ECOG Eastern Cooperative Oncology Group